Skip to main content
Erschienen in: Wiener klinische Wochenschrift 13-14/2020

20.07.2020 | Diabetes | main topic Zur Zeit gratis

Diabetes and COVID-19

Disease—Management—People

verfasst von: Slobodan Peric, MD, Prof. Thomas M. Stulnig, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 13-14/2020

Einloggen, um Zugang zu erhalten

Summary

The current pandemic of SARS-CoV‑2 coronavirus disease 2019 (COVID-19) is a particular challenge for diabetes patients. Diabetes mellitus predisposes to a particularly severe course of the disease and doubles the COVID-19 mortality risk due to pulmonary and cardiac involvement. In addition, diabetes patients often suffer from comorbidities which further worsen clinical outcomes. Glycemic control during infectious diseases is often suboptimal, and antidiabetic drugs and insulin therapy have to be adapted accordingly. On the other hand, access of diabetes patients to outpatient clinics are limited during the ongoing season urging alternative treatment options, particularly the implementation of novel telemedicine strategies. Hence, the opportunity of the COVID 19 crisis should be taken to make a significant step forward in the care for diabetes patients.
Literatur
1.
Zurück zum Zitat Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo IM, Halepoto DM, Iqbal M, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020;24(4):2012–9.PubMed Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo IM, Halepoto DM, Iqbal M, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020;24(4):2012–9.PubMed
6.
Zurück zum Zitat Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–4.CrossRef Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–4.CrossRef
7.
Zurück zum Zitat McKillop AM, Stevenson CL, Moran BM, Abdel-Wahab YHA, Flatt PR. Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion. Peptides. 2018;100:165–72.CrossRef McKillop AM, Stevenson CL, Moran BM, Abdel-Wahab YHA, Flatt PR. Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion. Peptides. 2018;100:165–72.CrossRef
8.
Zurück zum Zitat Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, et al. ACE and ACE2 activity in diabetic mice. Diabetes. 2006;55(7):2132–9.CrossRef Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, et al. ACE and ACE2 activity in diabetic mice. Diabetes. 2006;55(7):2132–9.CrossRef
14.
Zurück zum Zitat Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016;49:129–33.CrossRef Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016;49:129–33.CrossRef
15.
Zurück zum Zitat Chan-Yeung M, Xu R‑H. SARS: epidemiology. Respirology. 2003;8(s1):S9–S14.CrossRef Chan-Yeung M, Xu R‑H. SARS: epidemiology. Respirology. 2003;8(s1):S9–S14.CrossRef
17.
Zurück zum Zitat Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020b. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020b.
18.
Zurück zum Zitat Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.CrossRef Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.CrossRef
21.
Zurück zum Zitat Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.CrossRef Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.CrossRef
24.
Zurück zum Zitat Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7.CrossRef Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7.CrossRef
26.
Zurück zum Zitat Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020;14(3):211–2.CrossRef Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020;14(3):211–2.CrossRef
27.
Zurück zum Zitat Kohio HP, Adamson AL. Glycolytic control of vacuolar-type ATPase activity: a mechanism to regulate influenza viral infection. Virology. 2013;444(1–2):301–9.CrossRef Kohio HP, Adamson AL. Glycolytic control of vacuolar-type ATPase activity: a mechanism to regulate influenza viral infection. Virology. 2013;444(1–2):301–9.CrossRef
28.
Zurück zum Zitat Reading PC, Allison J, Crouch EC, Anders EM. Increased susceptibility of diabetic mice to influenza virus infection: compromise of collectin-mediated host defense of the lung by glucose? J Virol. 1998;72(8):6884–7.CrossRef Reading PC, Allison J, Crouch EC, Anders EM. Increased susceptibility of diabetic mice to influenza virus infection: compromise of collectin-mediated host defense of the lung by glucose? J Virol. 1998;72(8):6884–7.CrossRef
30.
Zurück zum Zitat Carey IM, Critchley JA, DeWilde S, Harris T, Hosking FJ, Cook DG. Risk of infection in type 1 and type 2 diabetes compared with the general population: a matched cohort study. Diabetes Care. 2018;41(3):513–21.CrossRef Carey IM, Critchley JA, DeWilde S, Harris T, Hosking FJ, Cook DG. Risk of infection in type 1 and type 2 diabetes compared with the general population: a matched cohort study. Diabetes Care. 2018;41(3):513–21.CrossRef
31.
Zurück zum Zitat Jaeckel E, Manns M, Von Herrath M. Viruses and diabetes. Ann Ny Acad Sci. 2002;958:7–25.CrossRef Jaeckel E, Manns M, Von Herrath M. Viruses and diabetes. Ann Ny Acad Sci. 2002;958:7–25.CrossRef
32.
Zurück zum Zitat Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23(6):623–8.CrossRef Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23(6):623–8.CrossRef
33.
Zurück zum Zitat Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193–9.CrossRef Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193–9.CrossRef
34.
Zurück zum Zitat Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4.CrossRef Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4.CrossRef
35.
Zurück zum Zitat Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL‑6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959–70.CrossRef Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL‑6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959–70.CrossRef
36.
Zurück zum Zitat Rogers LC, Lavery LA, Joseph WS, Armstrong DG. All feet on deck-the role of podiatry during the COVID-19 pandemic: preventing hospitalizations in an overburdened healthcare system, reducing amputation and death in people with diabetes. J Am Podiatr Med Assoc. 2020; https://doi.org/10.7547/20-051.CrossRefPubMed Rogers LC, Lavery LA, Joseph WS, Armstrong DG. All feet on deck-the role of podiatry during the COVID-19 pandemic: preventing hospitalizations in an overburdened healthcare system, reducing amputation and death in people with diabetes. J Am Podiatr Med Assoc. 2020; https://​doi.​org/​10.​7547/​20-051.CrossRefPubMed
39.
Zurück zum Zitat ÖDG. Information zu Covid-19 und Menschen mit Diabetes mellitus (Update 17.3.2020). 2020. ÖDG. Information zu Covid-19 und Menschen mit Diabetes mellitus (Update 17.3.2020). 2020.
40.
Zurück zum Zitat Dungan KM, Braithwaite SS, Preiser J‑C. Stress hyperglycaemia. Lancet. 2009;373(9677):1798–807.CrossRef Dungan KM, Braithwaite SS, Preiser J‑C. Stress hyperglycaemia. Lancet. 2009;373(9677):1798–807.CrossRef
41.
Zurück zum Zitat Mader JK, Brix J, Aberer F, Vonbank A, Resl M, Pieber TR, et al. Hospital diabetes management (Update 2019). Wien Klin Wochenschr. 2019;131(Suppl 1):200–11.CrossRef Mader JK, Brix J, Aberer F, Vonbank A, Resl M, Pieber TR, et al. Hospital diabetes management (Update 2019). Wien Klin Wochenschr. 2019;131(Suppl 1):200–11.CrossRef
42.
Zurück zum Zitat James MT, Grams ME, Woodward M, Elley CR, Green JA, Wheeler DC, et al. A meta-analysis of the association of estimated GFR, Albuminuria, diabetes mellitus, and hypertension with acute kidney injury. Am J Kidney Dis. 2015;66(4):602–12.CrossRef James MT, Grams ME, Woodward M, Elley CR, Green JA, Wheeler DC, et al. A meta-analysis of the association of estimated GFR, Albuminuria, diabetes mellitus, and hypertension with acute kidney injury. Am J Kidney Dis. 2015;66(4):602–12.CrossRef
43.
Zurück zum Zitat Mansfield KE, Nitsch D, Smeeth L, Bhaskaran K, Tomlinson LA. Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study. BMJ Open. 2016;6(12):e12690.CrossRef Mansfield KE, Nitsch D, Smeeth L, Bhaskaran K, Tomlinson LA. Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study. BMJ Open. 2016;6(12):e12690.CrossRef
45.
Zurück zum Zitat Umpierrez GE, Kitabchi AE. Diabetic ketoacidosis: risk factors and management strategies. Treat Endocrinol. 2003;2(2):95–108.CrossRef Umpierrez GE, Kitabchi AE. Diabetic ketoacidosis: risk factors and management strategies. Treat Endocrinol. 2003;2(2):95–108.CrossRef
46.
Zurück zum Zitat Faruque LI, Wiebe N, Ehteshami-Afshar A, Liu Y, Dianati-Maleki N, Hemmelgarn BR, et al. Effect of telemedicine on glycated hemoglobin in diabetes: a systematic review and meta-analysis of randomized trials. Can Med Assoc J. 2017;189(9):E341–E64.CrossRef Faruque LI, Wiebe N, Ehteshami-Afshar A, Liu Y, Dianati-Maleki N, Hemmelgarn BR, et al. Effect of telemedicine on glycated hemoglobin in diabetes: a systematic review and meta-analysis of randomized trials. Can Med Assoc J. 2017;189(9):E341–E64.CrossRef
Metadaten
Titel
Diabetes and COVID-19
Disease—Management—People
verfasst von
Slobodan Peric, MD
Prof. Thomas M. Stulnig, MD
Publikationsdatum
20.07.2020
Verlag
Springer Vienna
Schlagwörter
Diabetes
Coronavirus
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 13-14/2020
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-020-01672-3

Weitere Artikel der Ausgabe 13-14/2020

Wiener klinische Wochenschrift 13-14/2020 Zur Ausgabe

MUW researcher of the month

MUW researcher of the month

mitteilungen der gesellschaft der ärzte in wien

Veranstaltungstipps